Esophageal Gastrointestinal Stromal Tumor

Robb, William B.; Bruyère, Emilie; Amielh, D.; Vinatier, E.; Mabrut, J.‐Y.; Perniceni, Thierry; Piessen, Guillaume; Mariette, C.

doi:10.1097/sla.0000000000000505

Cited by 30 publications

(4 citation statements)

References 20 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enucleation surgery can be an alternative method which has a lower morbidity rate. Robb et al (14) showed that enucleation was safe for esophageal GIST cases, especially when smaller than 65 mm, considering an intact pseudocapsule with negative microscopic margins preserved. This patient was free of disease for 49 months by enucleation with clear margins.…”

Section: Discussionmentioning

confidence: 99%

Extra-Gastrointestinal Stromal Tumor of Prostate

Etıt¹,

Kar²,

Ekıncı³

et al. 2017

Balkan Med J

View full text Add to dashboard Cite

Background:Extra-gastrointestinal stromal tumor is defined as a mesenchymal neoplasm arising from soft tissues outside the gastrointestinal tract. Prostatic extra-gastrointestinal stromal tumor has rarely been noted.Case Report:A 56 year-old man presented with pain in the anal region. A digital rectal examination revealed that the prostate was markedly enlarged with a smooth, bulging surface. Computerized tomography images showed a 6 cm heterogeneous, infiltrative tumor within the prostate gland extending to the trigon of the bladder, left seminal vesicle and rectum. The tru-cut biopsy of the prostate was reported as leiomyoma. It was decided to perform surgery and the masses were easily and completely removed from the adjacent structures. The case was reported as extra-gastrointestinal stromal tumor within the intermediate- risk category with free surgical margins. Four years after the surgery, a locoregional failure was observed and treated with imatinib.Conclusion:Stromal tumor, although rare, should be considered in the differential diagnosis in patients with an enlarged prostate.

show abstract

Section: Discussionmentioning

confidence: 99%

Extra-Gastrointestinal Stromal Tumor of Prostate

Etıt¹,

Kar²,

Ekıncı³

et al. 2017

Balkan Med J

View full text Add to dashboard Cite

show abstract

“…Usually, these tumors are associated with nonspecific symptoms (early satiety, swelling) unless they ulcerate, bleed or grow enough to cause pain, obstruct, or present other manifestations related to their disproportionate size[ 12 , 13 ]. In the case of esophageal GIST, dysphagia represents the first specific symptom in this location[ 14 ].…”

Section: Role Of Clinicianmentioning

confidence: 99%

“…Robb et al[ 14 ] proposed that enucleation of the tumor is safe for esophageal GISTs < 65 mm as long as negative margins and intact pseudocapsule can be achieved, while in tumors of > 90 mm with evidence of mucosal ulceration and/or a high mitotic activity, an esophagectomy should be performed. The choice between esophagectomy and enucleation for tumors of between 65 and 90 mm needs further clarification with the decision being influenced by the location, malignant risk, patient comorbidity, and the presence of mucosal affectation[ 14 , 70 ]. Neoadjuvant therapy is indicated with the aim of shrinking the primary tumor[ 70 ].…”

Section: Resactable Diseasementioning

confidence: 99%

See 1 more Smart Citation

Gastrointestinal stromal tumors: A multidisciplinary challenge

Sánchez-Hidalgo¹,

Durán²,

Molero-Payan³

et al. 2018

WJG

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors located in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small asymptomatic lesions are frequently detected as incidental finding. Characteristically, most GISTs (> 95%) are positive for the KIT protein (CD117) by IHC staining and approximately 80%-90% of GISTs carry a mutation in the c-KIT or PDGFRA genes. Mutational analysis should be performed when planning adjuvant and neoadjuvant therapy, due to its possible resistance to conventional treatment. The arise of tyrosine kinase inhibitor has supposed a revolution in GISTs treatment being useful as adjuvant, neoadjuvant or recurrence disease treatment. That is why a multidisciplinary approach to this disease is required. The correct characterization of the tumor at diagnosis (the diagnosis of recurrences and the evaluation of the response to treatment with tyrosine kinase inhibitors) is fundamental for facing these tumors and requires specialized Endoscopist, Radiologists and Nuclear Medicine Physician. Surgery is the only potentially curative treatment for suspected resectable GIST. In the case of high risk GISTs, surgery plus adjuvant Imatinib-Mesylate for 3 years is the standard treatment. Neoadjuvant imatinib-mesylate should be considered to shrink the tumor in case of locally advanced primary or recurrence disease, unresectable or potentially resectable metastasic tumors, and potentially resectable disease in complex anatomic locations to decrease the related morbidity. In the case of Metastatic GIST under Neoadjuvant treatment, when there are complete response, stable disease or limited disease progression, complete cytoreductive surgery could be a therapeutic option if feasible.

show abstract